A new drug for Alzheimer's could reach the market in 2023

The pharmaceutical companies Eisai and Biogen have just announced to the press the results of their monoclonal antibody Lecanemab, a drug targeted at the deposit of amyloid in the brain. According to these data, administering it reduces cognitive impairment by 27% in people with Alzheimer's in the early stages or with Alzheimer-type cognitive impairment.

More information in the official press release:

The Ace Alzheimer Center Barcelona team has participated in the clinical trial of the drug, including 20% of patients from the 12 centers that participated in Spain. The experience acquired has given Ace professionals the knowledge and practice both in the detection of these cases and in the monitoring and management of possible adverse effects.

“This is great news for the Alzheimer's world: we are at a turning point in its history. We could have a drug with clinical efficacy in 2023,” says Dr. Mercè Boada, neurologist and medical director of Ace Alzheimer Center Barcelona.

Participation in this trial "consolidates our clinical trial team as an expert group for the prescription and administration of Lecanemab in people with mild cognitive impairment or mild-stage Alzheimer's," says Dr. Boada.

"It is necessary for our health system to start designing strategies that allow offering maximum safety to patients and diagnostic protocols that allow an adequate prescription to be made," adds Dr. Xavier Morató, director of clinical trials at Ace Alzheimer Center Barcelona.

"We hope that at the next international conference on clinical trials (CTAD), which will take place in November, we will obtain the most detailed information on the results of Lecanemab," concludes Dr. Boada.

You might also like

The United States approves the use of Aducanumab: a treatment for Alzheimer's disease

11/06/2021Day care and treatment
Ace Alzheimer Center Barcelona participated in Biogen's clinical trial for the drug Aducanumab. During the clinical trial, we were the sixth center that was able to include the most people in the study worldwide and the first in Europe.